Načítá se...

Selpercatinib: First Approval

Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drugs
Hlavní autor: Markham, Anthony
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716849/
https://ncbi.nlm.nih.gov/pubmed/32557397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01343-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!